Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability
2024年8月19日 - 9:00PM
Enovis™ Corporation (NYSE: ENOV), an innovation-driven
medical technology company, proudly unveils its Scandinavian Total
Ankle Replacement (STAR® Ankle), now with new e+™ Polyethylene.
Recent U.S. Food and Drug Administration (FDA) approval makes STAR®
Ankle the first and only mobile bearing ankle system with e+™
Polyethylene in the United States.1 The implant’s new vitamin
E-blended e+™ Polyethylene insert will offer improved durability,
stability, and longevity.1
"With e+™ Polyethylene, we uphold our commitment to the
advancement of our total ankle portfolio, merging full oxidative
resistance with the time-tested design of the STAR® Ankle,” said
Gary Justak, President and General Manager of Enovis Foot &
Ankle. “Building upon the proven success of the STAR® Ankle
epitomizes our culture of advancing foot and ankle solutions and
elevating patient treatment options. We don't just set the
standard—we redefine it.”
e+™ Polyethylene contains the free radical-neutralizing
antioxidant vitamin E; as a result, the material resists oxidation
and maintains consistent wear rates and stable mechanical
properties over time. In contrast, other highly crosslinked
polyethylenes are remelted during manufacturing to neutralize free
radicals2, a process that can reduce their mechanical strength by
up to 12%.1,3
“After extensive clinical experience with this superior material
in knee and shoulder implants, along with years of laboratory
testing, I expect improved patient outcomes through increased
polyethylene longevity. This builds on the outstanding STAR® Ankle
long-term metal-component survival rates seen in multiple clinical
studies,” stated Dr. Gregory Lundeen, a foot and ankle orthopedic
surgeon at Reno Orthopedic Center.
Combined with the recent release of STAR Patient Specific
Instrumentation (PSI), the STAR+ Experience represents Enovis’
commitment to continuous improvement, aimed at enhancing patient
satisfaction and outcomes. The integration of e+™ Polyethylene in
the STAR® Ankle continues to enhance the remarkable success of this
implant, which has been used globally over 40,000 times across its
37-year history.4
For more information about the STAR® Ankle with e+™ Polyethylene
and Enovis' innovative foot and ankle solutions, please visit
https://www.enovis.com/products/star-ankle.
Individual results may vary. Neither Enovis™
Corporation nor any of its subsidiaries dispense medical advice.
The contents of this release do not constitute medical, legal, or
any other type of professional advice. Rather, please consult your
healthcare professional for information on the courses of
treatment, if any, which may be appropriate for you.
Dr. Gregory Lundeen is a consultant for Enovis™ Corporation.
References
- e+ testing data on file. Bench test results not necessarily
indicative of clinical performance.
- Jennings et al. The influence of femoral condylar lift-off on
the wear of artificial knee joints. Proc Inst Mech Eng [H]. 2007
Apr;221(3):305-14.
- S.M. Kurtz. “The UHMWPE Handbook: Ultra-high Molecular Weight
Polyethylene in Total Joint Replacement”. Elsevier Academic Press,
2009.
- Enovis® internal document: Includes world-wide implantations of
all generations; newest generation has over 40,000 world-wide from
1998-2022
About Enovis
Enovis™ Corporation (NYSE: ENOV) is an innovation-driven medical
technology growth company dedicated to developing clinically
differentiated solutions that generate measurably better patient
outcomes and transform workflows. Powered by a culture of
continuous improvement, global talent and innovation, the Company’s
extensive range of products, services, and integrated technologies
fuels active lifestyles in orthopedics and beyond. For more
information about Enovis, please visit www.enovis.com.
Media Contact
Diana Aldermae
Enovis Foot & Ankle
Diana.Aldermae@enovis.com
MK-10554
- STAR® Ankle with e+™ Polyethylene
Enovis (NYSE:ENOV)
過去 株価チャート
から 11 2024 まで 12 2024
Enovis (NYSE:ENOV)
過去 株価チャート
から 12 2023 まで 12 2024